What is your preferred third-line treatment for a patient with metastatic renal cell carcinoma who has had progression of disease on both initial VEGFR-TKI therapy and second-line nivolumab?
For patients who remain fit and interested in treatment, but for whom a clinical trial is not an option, what systemic therapy do you reach for in this setting?
Answer from: Medical Oncologist at Community Practice
Cabozantinib can be even considered second line and keep Nivolumab as third line..
Answer from: Medical Oncologist at Academic Institution
As @Robert A. Figlin notes, there is little to no evidence that response to prior TKI influences subsequent response, although this is commonly used in clinical practice. After TKI, then nivolumab, I think another TKI is the current standard of care outside of a clinical trial. There is retrosp...
While a persons prior response to treatment is cho...